FDA-approved
Digestive & weight
Linaclotide
Evidence
FDA approved
Class
Guanylate cyclase-C agonist
KEY TAKEAWAY
Linaclotide is a 14-amino-acid peptide that stays in the gut and is barely absorbed into the blood. It is sold as Linzess. The FDA approved linaclotide (Linzess) in 2012 for irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Written by the Veylo editorial team · Updated
November 2026
What it is
Guanylate cyclase-C agonist
Approved for
Irritable bowel syndrome with constipation and chronic constipation
Key fact
The FDA approved linaclotide (Linzess) in 2012 for irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Route
Oral capsule once a day on an empty stomach
Evidence strength
FDA approved
Linaclotide is a 14-amino-acid peptide that stays in the gut and is barely absorbed into the blood. It is sold as Linzess.
It activates guanylate cyclase-C on the cells lining the intestine, which increases fluid secretion and speeds movement through the bowel. It may also calm pain-sensing nerves.
The FDA approved linaclotide (Linzess) in 2012 for irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
Irritable bowel syndrome with constipation and chronic constipation.
Diarrhea is the most common side effect and can be severe. The label carries a boxed warning against use in young children because of dehydration risk.
U.S. FDA prescribing information for Linaclotide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.